[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:t315i":3},{"name":4,"total":5,"recruiting":5,"trials":6},"T315I",3,[7,15,22],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT04260022","Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL",[11],"Phase 1","RECRUITING","2026-08-26T02:19:10.436356Z","2026-05-05T02:35:31.763995Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT01746836","Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib",[19],"Phase 2","2026-08-26T02:19:12.219640Z","2026-04-29T02:57:57.143397Z",{"nct_id":23,"title":24,"phases":25,"status":12,"updated_at":26,"content_modified":27},"NCT05805605","Allo HSCT Using RIC and PTCy for Hematological Diseases",[19],"2026-08-26T02:17:29.353236Z","2026-05-05T02:43:28.075410Z"]